📊 VCYT Key Takeaways
Is Veracyte, Inc.. (VCYT) a Good Investment?
Veracyte demonstrates exceptional profitability with 72.7% gross margins and 20.6% net margins in medical diagnostics, backed by a fortress balance sheet with zero debt and $263M cash. However, 174.9% net income growth and stagnant ROE (2.1%) and ROA (2.0%) raise sustainability questions and suggest inefficient capital deployment despite strong operational fundamentals.
Why Buy Veracyte, Inc.. Stock? VCYT Key Strengths
- Exceptional profitability margins (72.7% gross, 20.6% net) and strong FCF generation (23.2% margin)
- Zero debt with $263.1M cash and 9.31x current ratio providing substantial financial flexibility
- Revenue growth accelerating with 16% YoY increase and exceptional 174.9% net income growth YoY
- Medical laboratory services in recurring revenue healthcare sector with structural growth tailwinds
VCYT Stock Risks: Veracyte, Inc.. Investment Risks
- Extreme 174.9% net income growth appears unsustainable and likely represents one-time improvement rather than normalized run-rate
- Dangerously low ROE (2.1%) and ROA (2.0%) indicate company is deploying $1.3B equity inefficiently despite profitability
- Excessive cash position (9.31x current ratio) suggests potential capital deployment inefficiency or strategic uncertainty
- Regulatory risks in healthcare diagnostics and potential competitive commoditization of testing services
Key Metrics to Watch
- Net income growth normalization - track whether 174.9% jump was one-time event or sustainable improvement
- ROE and ROA trends - critical to understand if company improves capital deployment efficiency
- Free cash flow to revenue conversion - monitor sustainability of 23.2% FCF margin
- Revenue growth rate - whether 16% growth is maintained or decelerates in coming quarters
Veracyte, Inc.. (VCYT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 9.31x current ratio provides a solid financial cushion.
VCYT Profit Margin, ROE & Profitability Analysis
VCYT vs Healthcare Sector: How Veracyte, Inc.. Compares
How Veracyte, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Veracyte, Inc.. Stock Overvalued? VCYT Valuation Analysis 2026
Based on fundamental analysis, Veracyte, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Veracyte, Inc.. Balance Sheet: VCYT Debt, Cash & Liquidity
VCYT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Veracyte, Inc..'s revenue has grown significantly by 136% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.02 indicates the company is currently unprofitable.
VCYT Revenue Growth, EPS Growth & YoY Performance
VCYT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $114.5M | $7.0M | $0.09 |
| Q3 2025 | $115.9M | $15.2M | $0.19 |
| Q2 2025 | $114.4M | -$980.0K | $-0.01 |
| Q1 2025 | $96.8M | -$1.9M | $-0.02 |
| Q3 2024 | $90.1M | $15.2M | $0.19 |
| Q2 2024 | $90.3M | $3.9M | $0.05 |
| Q1 2024 | $82.4M | -$1.9M | $-0.02 |
| Q3 2023 | $75.6M | -$8.7M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Veracyte, Inc.. Dividends, Buybacks & Capital Allocation
VCYT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Veracyte, Inc.. (CIK: 0001384101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VCYT
What is the AI rating for VCYT?
Veracyte, Inc.. (VCYT) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VCYT's key strengths?
Claude: Exceptional profitability margins (72.7% gross, 20.6% net) and strong FCF generation (23.2% margin). Zero debt with $263.1M cash and 9.31x current ratio providing substantial financial flexibility.
What are the risks of investing in VCYT?
Claude: Extreme 174.9% net income growth appears unsustainable and likely represents one-time improvement rather than normalized run-rate. Dangerously low ROE (2.1%) and ROA (2.0%) indicate company is deploying $1.3B equity inefficiently despite profitability.
What is VCYT's revenue and growth?
Veracyte, Inc.. reported revenue of $139.1M.
Does VCYT pay dividends?
Veracyte, Inc.. does not currently pay dividends.
Where can I find VCYT SEC filings?
Official SEC filings for Veracyte, Inc.. (CIK: 0001384101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VCYT's EPS?
Veracyte, Inc.. has a diluted EPS of $0.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VCYT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Veracyte, Inc.. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is VCYT stock overvalued or undervalued?
Valuation metrics for VCYT: ROE of 2.1% (sector avg: 15%), net margin of 20.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VCYT stock in 2026?
Our dual AI analysis gives Veracyte, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VCYT's free cash flow?
Veracyte, Inc..'s operating cash flow is $35.2M, with capital expenditures of $3.0M. FCF margin is 23.2%.
How does VCYT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 20.6% (avg: 12%), ROE 2.1% (avg: 15%), current ratio 9.31 (avg: 2).